Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EPIK-B3 in advanced triple-negative breast cancer
2019-002637-11Phase 3Completed
- Sponsor
- Novartis
- Start
- Feb 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in triple-negative breast cancer (TNBC) comparing alpelisib + nab-paclitaxel with placebo + nab-paclitaxel (2 arms). Primary endpoint: Progression-free survival. Started Feb 2020; status: completed.
02
Drugs
alpelisib
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on 2019-002637-11.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-002637-11.